114870-03-0 磺达肝癸钠

生物活性 Fondaparinux sodium is an antithrombin-dependent factor Xa inhibitor. IC50 & Target Factor Xa[1] 体外研究 (In Vitro) Fondaparinux sodium is the first agent of a new class of anticoagulants that selectively target factor Xa. For Fondaparinux, its IC50 values (anti-Xa IU/ml) are 0.59±0.05 for activated monocytes (ac-M) and 0.17±0.03 for monocyte-derived microparticles (MMPs)[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 体内研究 (In Vivo) Fondaparinux sodium has a linear, dose-dependent pharmacokinetic profile, which provides a highly predictable response. Fondaparinux sodium is 100% bioavailable, has a rapid onset of action, and has a half-life of 14 to 16 hours, allowing for sustained antithrombotic activity over a 24-hour period. The drug does not affect prothrombin time or activated partial thromboplastin time, nor does it affect platelet function or aggregation. MCE has not independently confirmed the accuracy of these methods. They are for reference only.